PRCM
AMAG

Pine River Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Pine River Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-12,061
Closed -$282K – 625
2016
Q1 		$282K Buy
+12,061
New +$286K ﹤0.01% 601

Other funds holding AMAG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SIM
Stelliam Investment Management New York $404M AUM 5.1% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Pine River Capital Management's AMAG Position: Q2 2016 in Review

Pine River Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q2 2016, closing a stake of 12,061 shares — an estimated $282K sold.

Pine River Capital Management first reported a position in AMAG in Q1 2016 and held it in 1 quarter. The position peaked at $282K in Q1 2016. 165 funds tracked by Wall St. Rank hold AMAG as of Q2 2016.

  • Pine River Capital Management reported no remaining AMAG Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Pine River Capital Management sold 12,061 AMAG Pharmaceuticals shares in Q2 2016, an estimated $282K.
  • Pine River Capital Management first reported a position in AMAG Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Pine River Capital Management's AMAG Pharmaceuticals position peaked at $282K in Q1 2016.
  • 165 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2016.

Based on Pine River Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.